Harvey Capital Management Inc. Has $860,000 Stock Holdings in InMode Ltd. (NASDAQ:INMD)

Harvey Capital Management Inc. raised its holdings in InMode Ltd. (NASDAQ:INMD) by 1.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 51,490 shares of the healthcare company’s stock after acquiring an additional 700 shares during the period. Harvey Capital Management Inc.’s holdings in InMode were worth $860,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its stake in shares of InMode by 314.7% in the third quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after acquiring an additional 2,694 shares during the last quarter. Quarry LP grew its position in InMode by 154.3% in the 3rd quarter. Quarry LP now owns 3,781 shares of the healthcare company’s stock worth $64,000 after purchasing an additional 2,294 shares during the last quarter. National Bank of Canada FI increased its holdings in shares of InMode by 6.2% during the 3rd quarter. National Bank of Canada FI now owns 9,985 shares of the healthcare company’s stock worth $169,000 after purchasing an additional 579 shares during the period. GW Henssler & Associates Ltd. acquired a new position in shares of InMode during the third quarter valued at about $177,000. Finally, DGS Capital Management LLC bought a new stake in shares of InMode in the third quarter valued at about $182,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Trading Up 0.2 %

NASDAQ INMD opened at $18.58 on Wednesday. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $26.80. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of 7.91 and a beta of 2.13. The stock’s 50 day moving average is $17.34 and its two-hundred day moving average is $17.21.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. BTIG Research assumed coverage on InMode in a research note on Thursday, October 17th. They set a “buy” rating and a $25.00 price target on the stock. Barclays lifted their price objective on InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of InMode in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.00.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.